Effects of the COVID-19 pandemic on the management of ST-Segment elevation myocardial infarction in Indonesia: a cohort study
Open Access
- 8 June 2022
- journal article
- research article
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 629
Abstract
Background: ST-segment elevation myocardial infarction (STEMI) is a form of acute coronary syndrome with high mortality rate. Management of STEMI should be performed as soon as possible to prevent further damage. With the emergence of coronavirus disease 2019 (COVID-19), it may face obstacles. To overcome those problems, some changes in policy focusing on fibrinolytic therapy in STEMI patients have been applied. This study aimed to identify the effects of COVID-19 in management of STEMI patients in Indonesia. Methods: This retrospective study was conducted in Dr. Cipto Mangunkusumo Hospital (CMH), the national referral center in Indonesia. We compared data between 2018 to 2019 and 2020 to 2021 as before and during COVID-19 pandemic period, respectively. We analyzed the effects of COVID-19 on STEMI patients' visits to hospital i.e., monthly hospital admission and symptoms-to-hospital, management of STEMI i.e., the strategies and time of reperfusion, and clinical outcomes of STEMI patients i.e., major adverse coronary event and mortality. Results: There was a significant statistically reduced mean of monthly hospital admissions from 11 to 7 (p = 0.002) and prolonged duration of symptoms-to-hospital during COVID-19 from 8 to 12 hours (p = 0.005). There was also a decrease in primary percutaneous coronary intervention (PPCI) procedures during COVID-19 (65.2% vs. 27.8%, p<0.001), which was accompanied by an increased number of fibrinolytic (1.5% vs. 9.5%, p<0.001) and conservative therapy (28.5% vs. 55.6%, p <0.01). Moreover, there was also a prolonged duration of diagnosis-to-wire-crossing time (160 vs. 186 minutes, p = 0.005), meanwhile, percentage of urgent PCI, door-to-needle time, and clinical outcomes were not statistically significant. Conclusions: During COVID-19 pandemic, the number STEMI patients declined in monthly hospital admission, delays in symptoms-to-hospital time, changes in type of reperfusion strategy, and delays in PPCI procedures in CMH. Meanwhile, fibrinolytic time and clinical outcomes were not affected.Keywords
Funding Information
- This research is supported by Directorate of Research and Development, Universitas Indonesia under Hibah PUTI 2022 (NKB-413/UN2.RST/HKP.05.00/2022.)
This publication has 18 references indexed in Scilit:
- Management of acute coronary syndrome in patients with suspected or confirmed coronavirus disease 2019: Consensus from Taiwan Society of CardiologyJournal of the Formosan Medical Association, 2021
- Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry studyThe Lancet Public Health, 2020
- Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in ChinaJACC, 2020
- Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: Insights from a British cardiac centerAmerican Heart Journal, 2020
- Impact of COVID‐19 pandemic on ST‐elevation myocardial infarction in a non‐COVID‐19 epicenterCatheterization and Cardiovascular Interventions, 2020
- CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 EpidemicCirculation, 2020
- Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 eraEuropean Heart Journal, 2020
- Barriers to Covid-19 RT-PCR Testing in Indonesia: A Health Policy PerspectiveJournal of Indonesian Health Policy and Administration, 2020
- Management of ST‐segment‐elevation myocardial infarction during the coronavirus disease 2019 (COVID‐19) outbreak: Iranian“247” National Committee's position paper on primary percutaneous coronary interventionCatheterization and Cardiovascular Interventions, 2020
- Reperfusion Therapy for Acute Myocardial InfarctionDrugs, 1998